Compare HAFC & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAFC | AURA |
|---|---|---|
| Founded | 1982 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.5M | 797.5M |
| IPO Year | 2000 | 2021 |
| Metric | HAFC | AURA |
|---|---|---|
| Price | $32.14 | $6.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $32.17 | $20.00 |
| AVG Volume (30 Days) | 161.3K | ★ 789.7K |
| Earning Date | 04-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.75% | N/A |
| EPS Growth | ★ 22.44 | N/A |
| EPS | ★ 1.54 | N/A |
| Revenue | ★ $270,165,000.00 | N/A |
| Revenue This Year | $18.65 | N/A |
| Revenue Next Year | $7.28 | N/A |
| P/E Ratio | $20.73 | ★ N/A |
| Revenue Growth | ★ 15.28 | N/A |
| 52 Week Low | $22.85 | $4.73 |
| 52 Week High | $33.50 | $9.54 |
| Indicator | HAFC | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 56.13 | 40.67 |
| Support Level | $31.44 | $6.65 |
| Resistance Level | $32.70 | $7.18 |
| Average True Range (ATR) | 0.49 | 0.31 |
| MACD | 0.10 | -0.09 |
| Stochastic Oscillator | 87.23 | 8.37 |
Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.